Recombinant neuraminidase pseudotyped baculovirus: a dual vector for delivery of Angiotensin II peptides and DNA vaccine

Journal article

Authors/Editors

Strategic Research Themes

No matching items found.

Publication Details

Author list: Trianti I., Akeprathumchai S., Mekvichitsaeng P., Rachdawong S., Poomputsa K.

Publisher: SpringerOpen

Publication year: 2018

Journal: AMB Express (2191-0855)

Volume number: 8

Issue number: 1

ISSN: 2191-0855

eISSN: 2191-0855

URL: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85055093573&doi=10.1186%2fs13568-018-0699-8&partnerID=40&md5=a9fc94563ff6cf7e3aafc0d0aca1d9b4

Languages: English-Great Britain (EN-GB)

View in Web of Science | View on publisher site | View citing articles in Web of Science

Abstract

Baculovirus is a promising vaccine deliver vector due to its biosafety profiles, gene transfer efficiency, ability to display small foreign antigens on its surface, strong adjuvant activities, etc. A dual vector for peptide antigens and a DNA vaccine delivery was constructed. In this vector, a tetrameric glycoprotein neuraminidase (NA) from influenza A virus (H5N1) serves as a baculovirus surface protein to improve baculovirus transduction efficiency and a partner for displaying the target peptide antigen. Nucleotides encoding target peptides could be fused to a full length NA gene, at the lower part of its head structure, integrated into Autographa californica multinucleopolyhedrovirus genome and expressed under the control of a White Spot Syndrome Virus IE-1 shuttle promoter. Angiotensin II (AngII) peptides, a potent vasoconstrictor that causes high blood pressure, was our target antigen. The recombinant NA-AngII pseudotyped baculovirus had the AngII peptides fused to the NA and displayed on its surface. In vitro studies revealed that this recombinant baculovirus successfully delivered AngII peptides, as DNA vaccine, into human HEK293A cells. A single subcutaneous injection of the recombinant NA-AngII pseudotyped baculovirus into moderately high blood pressure rats at 4 ื 109 pfu/rat, stimulated anti-AngII antibody production and their systolic blood pressure (SBP) levels were found to have decreased. In addition, a single intranasal immunization at 8 ื 108 pfu/rat, raised anti-AngII antibodies in a rat and its SBP was also reduced. The recombinant neuraminidase pseudotyped baculovirus is a potential vector for AngII peptide antigen and DNA vaccine for subcutaneous or intranasal immunization for treatment of hypertension. ฉ 2018, The Author(s).

Keywords

AngII peptide vaccine, Angiotensin II (AngII), DNA vaccine, Neuraminidase (NA), Pseudotyped baculovirus